Daratumumab is a human IgGκ monoclonal antibody that targets CD38, which is highly expressed on myeloma cells and other hematopoietic cell types. 5,6 Daratumumab has direct and indirect antitumor ...

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical ...

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma ...

The committee concluded that daratumumab is well tolerated, improves quality of life for people who take it, and allows them to receive other treatments further down the pathway. The company's model ...

Please provide your email address to receive an email when new articles are posted on . The daratumumab-based regimen conferred significantly longer PFS than standard of care. Three-quarters of ...

RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving minimal residual ...

SAN DIEGO — In the MAIA study, adding the monoclonal antibody daratumumab (Darzalex, Janssen) to standard therapy significantly extended progression-free survival (PFS) in patients newly ...

Daratumumab significantly reduced progression risk in smoldering multiple myeloma, especially in high-risk patients, with a 64% reduction compared to active monitoring. The treatment did not ...

How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti-multiple myeloma (MM ...

1.1 Daratumumab plus bortezomib, thalidomide and dexamethasone is recommended, within its marketing authorisation, as induction and consolidation treatment for untreated multiple myeloma in adults, ...

Please provide your email address to receive an email when new articles are posted on . Daratumumab delayed progression of smoldering multiple myeloma compared with active monitoring. Among those ...